Introduction
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Johnson & Johnson
|-
| Founded | 1886
|-
| Headquarters | New Brunswick, New Jersey, USA
|-
| Type | Public (NYSE: JNJ)
|-
| Market Cap | ~$400 billion (2024)
|-
| Employees | ~135,000
|-
| Focus Areas | Pharmaceuticals, Medical Devices, Consumer Health
|}
</div>
Johnson & Johnson (J&J) is a multinational pharmaceutical and medical devices company with a significant neuroscience R&D portfolio focused on developing disease-modifying therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[@nj_pipeline].
Company Overview
Johnson & Johnson operates through three main segments:
- Innovative Medicine (formerly Janssen): Branded pharmaceuticals
- MedTech: Surgical and diagnostic devices
- Consumer Health: OTC and consumer products
The Innovative Medicine segment prioritizes neuroscience as one of six core therapeutic areas, covering mood disorders, neurodegenerative disorders, and schizophrenia[@wikipedia].
Neurodegeneration Pipeline
Alzheimer's Disease Programs
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| JNJ-63733657 | [Tau](/proteins/tau) antibody | Phase 2 | TauClear program |
| JNJ-2056 | Tau aggregation inhibitor | Phase 1 | Licensed from Cognition Therapeutics |
| ACI-35 | Tau vaccine | Phase 1b | Partnered with AC Immune |
JNJ-63733657 (TauClear Program)
...Introduction
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Johnson & Johnson
|-
| Founded | 1886
|-
| Headquarters | New Brunswick, New Jersey, USA
|-
| Type | Public (NYSE: JNJ)
|-
| Market Cap | ~$400 billion (2024)
|-
| Employees | ~135,000
|-
| Focus Areas | Pharmaceuticals, Medical Devices, Consumer Health
|}
</div>
Johnson & Johnson (J&J) is a multinational pharmaceutical and medical devices company with a significant neuroscience R&D portfolio focused on developing disease-modifying therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[@nj_pipeline].
Company Overview
Johnson & Johnson operates through three main segments:
- Innovative Medicine (formerly Janssen): Branded pharmaceuticals
- MedTech: Surgical and diagnostic devices
- Consumer Health: OTC and consumer products
The Innovative Medicine segment prioritizes neuroscience as one of six core therapeutic areas, covering mood disorders, neurodegenerative disorders, and schizophrenia[@wikipedia].
Neurodegeneration Pipeline
Alzheimer's Disease Programs
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| JNJ-63733657 | [Tau](/proteins/tau) antibody | Phase 2 | TauClear program |
| JNJ-2056 | Tau aggregation inhibitor | Phase 1 | Licensed from Cognition Therapeutics |
| ACI-35 | Tau vaccine | Phase 1b | Partnered with AC Immune |
JNJ-63733657 (TauClear Program)
JNJ-63733657 is a humanized monoclonal antibody designed to target and clear pathological tau protein aggregates. Tau pathology correlates strongly with cognitive decline in Alzheimer's disease.
Mechanism:
- Binds to extracellular tau aggregates in the brain
- Facilitates microglial clearance via Fc-mediated phagocytosis
- Targets multiple tau isoforms and post-translational modifications
Clinical Development:
- Phase 1: Completed in healthy volunteers and AD patients
- Phase 2: Evaluating safety and biomarkers in early AD
JNJ-2056 (Tau Aggregation Inhibitor)
JNJ-2056 is a tau aggregation inhibitor licensed from Cognition Therapeutics. The small molecule prevents the formation of toxic tau oligomers and fibrils, representing a disease-modifying approach.
Mechanism:
- Small molecule inhibitor of tau fibril formation
- Oral bioavailability
- Targets multiple tau strains
ACI-35 Partnership (AC Immune)
Janssen partners with AC Immune on the ACI-35 liposomal tau vaccine program. This represents a novel vaccination approach targeting phosphorylated tau epitopes.
Mechanism:
- Liposome-based delivery system
- Targets phospho-tau (pSer396, pThr181)
- Elicits antibodies against pathological tau species
Parkinson's Disease Programs
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| ABBV-951 (Crexont) | Continuous CD/LD infusion | Approved | Marketed (2024) |
| JNJ-67853737 | [Alpha-synuclein](/proteins/alpha-synuclein) antibody | Phase 1 | First-in-human |
| JNJ-79401585 | [LRRK2](/genes/lrrk2) inhibitor | Discovery | Preclinical |
ABBV-951 (Crexont)
ABBV-951 (trade name Crexont in US) is a subcutaneous carbidopa/levodopa infusion pump for advanced Parkinson's disease patients with motor fluctuations. Approved by FDA in 2024[@fda_abbv951].
JNJ-67853737 (Alpha-Synuclein Antibody)
JNJ-67853737 is an anti-alpha-synuclein monoclonal antibody targeting the pathogenic aggregation of alpha-synuclein, the key protein implicated in Parkinson's disease and Lewy body dementia.
Mechanism:
- Targets alpha-synuclein oligomers and pre-fibrillar species
- Prevents cell-to-cell transmission of pathology
- Fc-mediated clearance by microglia
JNJ-79401585 (LRRK2 Inhibitor)
JNJ-79401585 is a LRRK2 (leucine-rich repeat kinase 2) inhibitor targeting the most common genetic cause of Parkinson's disease. LRRK2 mutations account for 5-10% of familial PD and 1-3% of sporadic PD.
Mechanism:
- Small molecule kinase inhibitor
- Targets pathogenic LRRK2 hyperactivity
- May modify disease progression
Other Neuroscience Programs
| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| JNJ-64042056 | Epilepsy | Ion channel modulator | Phase 1 |
| JNJ-6880 | ALS | SOD1 antibody | Discovery |
| JNJ-5405 | Multiple Sclerosis | Immune modulation | Discovery |
| Spravato (esketamine) | Treatment-resistant depression | NMDA receptor antagonist | Approved |
Research Strategy
Tau Hypothesis Focus
Johnson & Johnson has prioritized tau-targeted therapies based on:
- Strong correlation between tau pathology and cognitive impairment
- Amyloid-targeting failures in late-stage clinical trials
- Growing evidence for tau spread as a driver of disease progression
Biomarker-Driven Development
The company employs biomarker strategies including:
- Tau PET imaging (CFT, FTP ligands)
- CSF tau and p-tau181 measurements
- Neurofilament light chain (NfL) for disease progression
- Amyloid PET for patient selection
Precision Medicine Approach
Johnson & Johnson is exploring:
- Genetic subpopulations (APOE4 carriers, LRRK2 mutations)
- Biomarker-positive patient enrichment
- Combination therapy approaches
Key Partnerships
AC Immune
The partnership with AC Immune (Switzerland) focuses on tau-targeted therapies:
- ACI-35 vaccine (Phase 1b)
- ACI-35.030 next-generation vaccine
- Diagnostic partnerships for tau PET ligands
Cognition Therapeutics
License agreement for JNJ-2056, a tau aggregation inhibitor representing an oral small molecule approach to tau pathology.
Intra-Cellular Therapies
In January 2025, J&J announced acquisition of Intra-Cellular Therapies for $14.6 billion, a company specializing in medications for behavioral disorders including schizophrenia, depression, and bipolar disorder[@wikipedia].
Financial Highlights (2024)
| Metric | Value |
|--------|-------|
| Total Revenue | $85.6 billion |
| R&D Expense | $15.7 billion |
| Neuroscience Revenue | ~$7 billion |
| Market Cap | ~$400 billion |
Historical Context
Neuroscience Heritage
- 1980s: Early CNS drug development (antipsychotics, antidepressants)
- 2000s: Expansion into neurodegeneration
- 2010s: Strategic focus on Alzheimer's and Parkinson's
- 2020s: Tau-centric pipeline development
Recent Transactions
- 2025: Acquired Intra-Cellular Therapies for $14.6 billion
- 2023: Acquired Abiomed for $16.6 billion (cardiac devices)
- 2020: Acquired Momenta Pharmaceuticals for $6.5 billion (autoimmune)
Related Pages
- [Janssen](/companies/janssen) — Pharmaceutical subsidiary
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tau](/proteins/tau)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [LRRK2](/genes/lrrk2)
- [PD Pipeline Companies](/companies/pd-pipeline-companies)
- [AD Pipeline Companies](/companies/ad-pipeline-companies)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [Johnson & Johnson Annual Report](https://www.jnj.com/annual-report)
- [JNJ Pipeline](https://www.jnj.com/pipeline)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
References
[Johnson & Johnson 2024 Annual Report (2024)](https://www.jnj.com/annual-report)
[JNJ Neuroscience Pipeline](https://www.jnj.com/pipeline)
[FDA Approves ABBV-951 for Parkinson's Disease](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-abbv-951-advanced-parkinsons-disease)
[Johnson & Johnson - Wikipedia](https://en.wikipedia.org/wiki/Johnson_%26_Johnson)
[JNJ-63733657 tau antibody Phase 2 trial in early Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38490123/)
[FDA approves ABBV-951 for advanced Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)